FDA grants Seattle Genetics' Adcetris orphan rating in MF

27 November 2012

US biotech firm Seattle Genetics (Nasdaq: SGEN) says its Adcetris (brentuximab vedotin) has been granted orphan drug designation by the US Food and Drug Administration for the treatment of mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma (CTCL).

Seattle Genetics and its Adcetris collaborator, Millennium, a US unit of Japan’s largest drugmaker Takeda (TYO: 4502), are conducting the ALCANZA trial, a Phase III clinical trial of the drug for patients with CD30-positive relapsed CTCL, including MF, and indication that is not as yet approved by the agency.

“This orphan drug designation is a part of our Adcetris regulatory strategy, designed to complement the Special Protocol Assessment for the ongoing ALCANZA study,” said Clay Siegall, president and chief executive of Seattle Genetics, adding: “The encouraging data from investigator-sponsored trials of Adcetris in CTCL, which will be presented at ASH, provide further support for our activities in this patient population.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology